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New insights in uremic toxins. The retention in the body of The retention compounds, which are considered re-
compounds, which normally are secreted into the urine results sponsible for the uremic syndrome, are uremic toxins.
in a clinical picture, called the uremic syndrome. The retention Before a retention solute can be accepted as a true ure-compounds responsible for the uremic syndrome are called
mic toxin, it should comply, however, with a number ofuremic toxins. Only a few of the uremic retention solutes fully
conditions: (1) Such a compound should be chemicallyconform to a true definition of uremic toxins. Uremic patients
develop atheromatotic vascular disease more frequently and identified and accurate quantitative analysis in biological
earlier than the general population. The classical risk factors fluids should be possible; (2) the total body and plasma
seem to be less important. Other factors have been suggested levels should be higher in uremic than in nonuremicto be at play, and among those uremic toxins are mentioned
subjects. (3) high concentrations should be related toas potential culprits. The identification, classification and char-
specific uremic dysfunctions and/or symptoms that de-acterization of the solutes responsible for vascular problems
seems of utmost importance but is far from complete due crease or disappear when the concentration is reduced;
to a lack of standardization and organization. The European (4) biological activity, conforming to clinical changes ob-
Uremic Toxin Work Group (EUTox) has as a primary aim to
served in conjunction with the uremic syndrome, shoulddiscuss, analyze and offer guidelines in matters related to the
be proven in in vivo, ex vivo, or in vitro studies; and (5)identification, characterization, analytical determination and
evaluation of biological activity of uremic retention solutes. concentrations in these studies should conform to those
The final aim remains the development of new strategies to found in body fluids or tissue of uremic patients [5].
reduce the concentration of the most active uremic solutes. Obviously, only a few of the uremic retention solutes
These activities will at first be concentrated on reducing factors
fully conform to the definition of a true uremic toxin,influencing cardiovascular morbidity and mortality.
and even those might be a matter of debate (e.g., H2O,
phosphate, potassium, 2-microglobulin). One of the ma-
DEFINITIONS jor problems arising in this area is that many of the
Since many decades, the problem of uremic toxicity compounds with a presumed or proven biologic potential
has been a major area of concern for the entire nephro- are difficult to remove by conventional dialysis, either be-
logic community. The retention in the body of com- cause of their molecular weight and/or as a consequence
pounds that normally are secreted into the urine by the of their protein binding. As a result, number 3 of the
healthy kidneys gives rise to a progressive deterioration above-mentioned conditions is especially difficult to cor-
of physiologic functions and of the clinical condition. roborate. On the other hand, if clinical proof of benefit
The resulting clinical picture is the uremic syndrome. by removal remains absent, the impetus for researchers
If uremic retention solutes are considered as such with- or industries to produce devices or other methodologies
out necessarily proven toxicity, at least 90 organic com- of potential help for the removal of these molecules
pounds have been retained in uremia [1]. The most im- usually remains minimal. This results in a vicious circle,
portant known organic uremic retention solutes are whereby technologic/pharmacologic innovations to re-
listed in Table 1. To this list should be added a number move solutes other than the classic compounds, such as
of inorganic substances, such as water, potassium, phos- urea, are limited or even nonexistent.
phate, and the trace elements [2–4]. This is probably only
the tip of the iceberg, and many more still unidentified
UREA AS A UREMIC RETENTION SOLUTE/solutes are possibly retained and might exert toxicity.
UREMIC TOXIN
One of the most typical examples of the sometimes-1 For the members of EUTox, see the Appendix.
confusing state of the art in the area of uremic toxicity
Key words: uremic syndrome, toxins, EUTox. is the current knowledge about urea. Urea is a 60-dalton
small water-soluble compound, which has among the 2003 by the International Society of Nephrology
S-6
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Table 1. Main known uremic retention solutes
Small water soluble solutes Protein-bound solutes Middle molecules
Asymmetric dimethylarginine 3-Deoxyglucosone Adrenomedullin
Benzylalcohol CMPF Atrial natriuretic peptide
-Guanidinopropionic acid Fructoselysine 2-Microglobulin
-Lipotropin Glyoxal -Endorphin
Creatinine Hippuric acid Cholecystokinin
Cytidine Homocysteine Clara cell protein
Guanidine Hydroquinone Complement factor D
Guanidinoacetic acid Indole-3-acetic acid Cystatin C
Guanidinosuccinic acid Indoxyl sulfate Degranulation inhibiting protein I
Hypoxanthine Kinurenine Delta-sleep-inducing peptide
Malondialdehyde Kynurenic acid Endothelin
Methylguanidine Methylglyoxal Hyaluronic acid
Myoinositol N-carboxymethyllysine Interleukin 1
Orotic acid P-cresol Interleukin 6
Orotidine Pentosidine Kappa-Ig light chain
Oxalate Phenol Lambda-Ig light chain
Pseudouridine P-OHhippuric acid Leptin
Symmetric dimethylarginine Quinolinic acid Methionine-enkepahlin
Urea Spermidine Neuropeptide Y
Uric acid Spermine Parathyroid hormone
Xanthine Retinol binding protein
Tumor necrosis factor alpha
CMPF is carboxy-methyl-propyl-furanpropionic acid.
presently known uremic retention solutes the highest The global experience regarding urea teaches us that
concentration in uremic serum. It has been used as a uremic toxicity is neither a question of retention of urea
marker of uremic retention and removal for several years alone, nor of water-soluble compounds alone; in the
[6], and its removal is directly related to patient survival treatment of the uremic syndrome, hence, more than the
[7]. Nevertheless, there are very few studies demonstra- removal of urea alone should be pursued. It should be
ting a direct biologic impact of urea at currently encoun- realized that urea removal is not representative for many
tered uremic concentrations [8], and those studies show other molecules, and that this is especially the case for
an impact that not necessarily concentrates on key or- hard to remove molecules, such as protein-bound solutes
ganic functions in the biochemical/biologic status of the or the middle molecules (500 daltons) [12]. Many of
human body. these molecules exert biologic and/or clinical acivities
When urea was added to the dialysate during a period [8]. Among the few small water-soluble uremic retention
of several months at concentrations largely exceeding compounds that have been shown to exert biologic ac-
those currently encountered in dialyzed uremics, uremic tion, many again have an intradialytic kinetic behavior
symptomatology was not consistently altered over the that is indisputably different from that of urea (e.g., the
entire study period [9], again suggesting that by itself, guanidines, phosphate, xanthine, and hypoxanthine [13]).
urea is not very important in the development of uremic
Cardiovascular morbidity and mortality astoxicity.
a uremic problemIt is difficult to explain the apparent paradox between
the validity of urea as a marker and its presumed lack Uremic patients develop atheromatotic vascular disease
more frequently and earlier than the general populationof toxicity. Of note, urea removal seems to be related as
a surrogate marker only indirectly to survival, and not [14, 15]. The classic risk factors affecting the general popu-
lation, such as hypercholesterolemia or hypertension,to quality of life. One possibility to consider is that urea
removal by itself does not affect survival, but that it is seem to have less weight in the development of vascular
problems in uremia [16, 17]. Other elements have beenrepresentative for the removal of one or more other
solutes with a more consistent impact. One such potential suggested to be at play, and among those, uremic toxins
have been mentioned as potential culprits [17]. Dialyticculprit is potassium, another small-water soluble com-
pound known to substantially affect dialytic survival [4]. treatment seems to have no major impact on the evolution
of this process. The latter observation indicates that theAnother possibility is that, together with urea, other
uremic solutes antagonizing its toxic impact are retained current concept of dialysis, with major emphasis on re-
moval of water-soluble compounds, is insufficient to pre-[10]. Finally, urea might be at the origin of other, more
toxic moieties, such as some of the guanidines or carba- vent or slow down cardiovascular damage. In line with this
observation, scattered studies based on different method-mylation products [8, 11].
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ologies and evaluating different solutes show that most, review of the presently known uremic retention solutes
was recently finalized and submitted; this publicationif not all, compounds which up until now have been
suggested to play a role in atherogenesis, show a dialytic contains a classification according to solute characteris-
tics, and information about their concentration (see be-behavior which is different from that of urea: advanced
glycation end products (AGEs), advanced oxidation pro- low) [1]. In June 2002, an Expression of Interest (EoI)
was submitted to the European Community in the con-tein products (AOPP), homocysteine, phosphate, asym-
metric dimethylarginine (ADMA), and cytokines [5]. text of the 6th Framework Program (FP-6). Currently,
the group is involved in the definition of standardizedHence, the identification, classification, and character-
ization of the clinical importance of the solutes responsi- evaluation procedures for in vitro and in vivo research
(inclusive high through-put and proteome analysis).ble for cardiovascular morbidity and mortality is of ut-
most importance to improve survival and quality of life More information on the intentions and structure can
be obtained from the web site of the group: http://www.of the uremic population before and after the start of
dialysis. Only subsequent to this can the development uremic-toxins.org.
The review of the existing retention solutes is basedof specific devices pursuing the removal of those com-
pounds be launched. Finally, the possibility should be on a literature search of 857 publications, of which 141
deal with concentration [1]. Those publications appearedconsidered that the same factors might be at play in the
general population. in the literature from 1968 to 2002. To compose the final
lists, information from 55 publications covering 90 sol-This search for the responsible solutes is, however,
flawed by a number of confounding factors, especially for utes was used, and the resulting tables display the mean
(median) concentration in the normal population, thein vitro studies: (1) the difficulty to define adequate mea-
sures to guarantee purity of samples (prevention of con- mean (median) concentration in the uremic population
(highest reported value), the highest single concentrationtamination with lipopolysaccharides or other contami-
nants); (2) the lack of a systematic coordinated approach ever reported, and the molecular weight. This publica-
(up until now, several research groups applied differently tion offers a guideline regarding the concentrations to
prepared compounds in different experimental set-ups be pursued for future in vitro or in vivo studies.
at incorrect concentrations, not conforming to those en- Solutes were subdivided into small water-soluble com-
countered in clinical uremia); and (3) the lack of consid- pounds (non–protein-bound), protein-bound compounds,
eration of intermutual influences among various solutes and middle molecules. Sixty-eight molecules had a MW
when they are present together in the uremic milieu. 500 daltons, whereas 22 compounds were classified as
It is of note that those problems are not specific for middle molecules (500 daltons). Twelve molecules had
uremic toxin research in the area of cardiovascular com- a molecular weight in excess of 12,000 daltons. Twenty-
plications, but that they are equally relevant for any other five solutes were protein bound; these were mostly small
aspect of the uremic syndrome (e.g., uremic anemia, compounds with a MW 500 daltons but included also
progression of the loss of residual renal function, etc.). the middle molecules leptin and retinol-binding protein.
Concentrations range from ng/L (methionine-enkepha-
The European Uremic Toxin Work Group (EUTox) lin) up to g/L (urea).
While recognizing the problems related to an insuffi- This review further contains reflections on the interin-
ciently coordinated approach in the area of uremic toxin dividual variability of these concentrations (e.g., the ratio
research, the European Uremic Toxin Work Group between uremic and normal concentration, the scatter
(EUTox) started its activities in the autumn of 2000. This of concentrations in the uremic population, and the dif-
group is made up of several European researchers who ferences in concentration among various publications).
have been active in this field for many years, together Indisputably, such a list will necessitate regular updat-
with representatives of the major industries active in ing, with the introduction of newly detected compounds,
dialysis treatment. This group was installed under the as well as newly defined concentrations of already known
auspices of the European Society for Artificial Organs compounds. The plan is to display the lists on the web
(ESAO). site of the Work Group, where it will be made possible
The primary aim of this group is to discuss, analyze, to contact the Work Group concerning newly identified
and offer guidelines in matters related to the identifica- solutes and/or concentrations which are aberrant from
tion, characterization, analytical determination, and eval- those reported in the Work Group’s lists.
uation of biologic activity of uremic retention solutes.
The Work Group has accomplished and is working on
MODIFICATIONS IN THE THERAPEUTIC/a number of projects. In October 2001, a common text
PREVENTIVE APPROACHendorsed by all members of the group presenting a state
While extending our knowledge about solutes respon-of the art in the area of uremic toxicity, especially in
relation to cardiovascular events, was published [5]. A sible for the uremic syndrome, the final aim remains the
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Fig. 1. Possible preventive or therapeutic measures in the context of uremic cardiovascular disease.
development of new strategies to reduce the concentra- organs, application of alternative time frames for extra-
corporeal solute removal, development of alternativetion of the most active uremic retention solutes.
diets, and development of new drugs and/or regenerativeIn what follows we will depict the therapeutic/preven-
medicine.tive options for cardiovascular disease (Fig. 1, diagram-
matic summary), but similar flow charts could be com-
Reprint requests to R. Vanholder, Nephrology Section, Department
posed for any aspect of the uremic problem. Some of of Internal Medicine, University Hospital, De Pintelaan, 185, B9000,
Gent, Belgium.the solutions will overlap with those presented here, but
E-mail: raymond.vanholder@rug.ac.besome will be specific for these alternative problems and,
hence, different. The complexity of the final solutions
for the uremic problem that can be proposed or thought APPENDIX
of is striking. In what follows and in the Fig. 1, only mea- Members of EUTox include: A. Argile´s, Institute of Human Genet-
sures which are directly or indirectly related to a decrease ics, IGH-CNRS UPR 1142, Montpellier, France; U. Baurmeister, MAT
Adsorption Technologies, Obernburg, Germany; P. Brunet, Nephrol-of solute concentration and/or a decrease of inflamma-
ogy–Internal Medicine, Ste. Marguerite Hospital, Marseille, France; W.tion are mentioned, such as the correct identification of Clark, Baxter Healthcare Corporation, Lessines, Belgium; G. Cohen,
the responsible toxins, so that more direct removal strat- Division of Nephrology, Department of Medicine, University of Vi-
enna, Vienna, Austria; P.P. De Deyn, Department of Neurology, Mid-egies can be developed, the enhancement of solute re-
delheim Hospital, Laboratory of Neurochemistry and Behaviour, Uni-moval, the development of devices for extracorporeal versity of Antwerp, Belgium; R. Deppisch, Gambro Corporate Re-
adsorption of solutes, the application of strategies to re- search, Hechingen, Germany; B. Descamps-Latscha, INSERM Unit
507, Necker Hospital, Paris, France; T. Henle, Institute of Food Chem-duce the input of solutes or solute precursors via the gas-
istry, Technical University, Dresden, Germany; A. Jo¨rres, Nephrologytrointestinal system, the decrease of the Ca  P-product and Medical Intensive Care, UK Charite´, Campus Virchow-Klinikum,
and hyperparathyroidism, the modification of toxin me- Medical Faculty of Humboldt-University, Berlin, Germany; H.D.
Lemke, Membrana GmbH, Obernburg, Germany; Z.A. Massy, Divi-tabolism, and the maintenance of residual renal function.
sion of Nephrology, CH-Beauvais, and INSERM Unit 507, NeckerThese preventive measures will come to pass only Hospital, Paris, France; J. Passlick-Deetjen, Fresenius Medical Care,
through the application of new research and therapeutic Bad Homburg, Germany; M. Rodriguez, University Hospital Reina
Sofia, Research Institute, Cordoba, Spain; B. Stegmayr, Norrlandsoptions, such as high through-put, proteome and genome
University Hospital, Division of Nephrology, Department of Medicine,
analysis, development of new extracorporeal removal Umea, Sweden; P. Stenvinkel, Nephrology Department, University
Hospital, Huddinge, Sweden; C. Tetta, Fresenius Medical Care, Badsystems such as adsorptive devices and hybrid artificial
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